What is the dosage of Erbitux?

Erbitux is available in 2 dosages, including 2 mg/ml Injection 100 ml and 2 mg/ml Injection 50 ml

What does Erbitux treat?

Erbitux treats Squamous Cell Carcinoma

What is Erbitux made of?

Erbitux contains cetuximab which is a Epidermal Growth Factor Receptor Antagonist

How is Erbitux administered?

Erbitux is administered as a Injectable

What is Erbitux mechanism of action?

Erbitux mechanism of action is HER1 Antagonists

Dosage & Administration Efficacy safety testing Drug label Prior authorization Financial assistance

Patient education

Erbitux

(cetuximab)

100 ML cetuximab 2 MG/ML Injection [Erbitux]50 ML cetuximab 2 MG/ML Injection [Erbitux]

BLACK BOX WARNING

Dosage & administration

* Premedicate with an H1 receptor antagonist.
* In Combination With Radiation Therapy:
* Initial dose: 400 mg/m2 administered as a 120-minute intravenous infusion one week prior to initiating a course of radiation therapy.
* Subsequent doses: 250 mg/m2 administered as a 60-minute infusion every week for the duration of radiation therapy (6–7 weeks).
* Complete ERBITUX administration 1 hour prior to radiation therapy.

* As Single-Agent or in Combination With Chemotherapy:
* Weekly: Administer initial dose of 400 mg/m2 as a 120-minute intravenous infusion, and subsequent doses of 250 mg/m2 infused over 60 minutes once weekly.
* Biweekly: Administer 500 mg/m2 as a 120-minute intravenous infusion every two weeks.
* Complete ERBITUX administration 1 hour prior to chemotherapy. Continue treatment until disease progression or unacceptable toxicity.

* See full prescribing information for dosage adjustments for adverse reactions.

eficacy, safety & testing

Erbitux clinical details

Dosing

Metastatic Colorectal Cancer

BRAF V600E Mutant mCRC

Locoregionally Advanced SCCHN

Metastatic SCCHN

drug label

Erbitux prescribing information

Have more Erbitux questions?

Submit MSL Request

Learn More

Need to report an Erbitux issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Erbitux Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

NOT PROVIDED BY BRANDComplete Coverage Authorization appeals

Coverage Authorization Appeals (First-Level)

Coverage Authorization Appeals (Second Level)

Denied Claims Checklist

First-Level Medicare Review Letter

Second-Level Medicare Review Letter

Learn More

Benefits investigation

Lilly Oncology Support - Erbitux Enrollment Form

Lilly Oncology Support - Erbitux Enrollment Form (Online)

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Erbitux Financial assistance options

Co-pay savings program

commercial only

Lilly Oncology Support - Erbitux Enrollment Form

Enroll in Patient Savings Program

Lilly Oncology Support - Erbitux Enrollment Form (Online)

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Lilly Cares Foundation

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Erbitux Patient education

Getting started on Erbitux

NOT PROVIDED BY BRANDInstructions For Use: Locally Advanced SCCHN

NOT PROVIDED BY BRANDInstructions For Use: Metastatic SCCHN

NOT PROVIDED BY BRANDInstructions For Use: Metastatic CRC

NOT PROVIDED BY BRANDInstructions For Use: BRAF V600E Mutant mCRC